Sphingosine 1-phosphate (S1P) signaling regulates lymphocyte egress from lymphoid organs into systemic circulation. The sphingosine phosphate receptor 1 (S1P 1 ) agonist FTY-720 (Gilenya) arrests immune trafficking and prevents multiple sclerosis (MS) relapses. However, alternative mechanisms of S1P-S1P 1 signaling have been reported. Phosphoproteomic analysis of MS brain lesions revealed S1P 1 phosphorylation on S351, a residue crucial for receptor internalization. Mutant mice harboring an S1pr1 gene encoding phosphorylation-deficient receptors (S1P 1 (S5A)) developed severe experimental autoimmune encephalomyelitis (EAE) due to autoimmunity mediated by interleukin 17 (IL-17)-producing helper T cells (T H 17 cells) in the peripheral immune and nervous system. S1P 1 directly activated the Jak-STAT3 signal-transduction pathway via IL-6. Impaired S1P 1 phosphorylation enhances T H 17 polarization and exacerbates autoimmune neuroinflammation. These mechanisms may be pathogenic in MS.
A r t i c l e s
The development of FTY-720 (Fingolimod, Gilenya) as a first-line oral therapy in MS has shown that sphingosine-1-phosphate (S1P) signaling is a targetable pathway in autoimmune neuroinflammation [1] [2] [3] [4] . One of the best-characterized functions of the S1P pathway is the regulation of lymphocyte trafficking from secondary lymphoid organs into systemic circulation [5] [6] [7] . Interaction of the sphingolipid ligand S1P in the blood or lymph with the G protein-coupled receptor (GPCR) S1P receptor 1 (S1P 1 ) on lymphocytes is necessary for their egress from the spleen and lymph nodes into systemic circulation [8] [9] [10] . The crucial role of the S1P-S1P 1 interaction in trafficking is perturbed by FTY-720, a functional antagonist of S1P 1 (refs. 5,11,12) . FTY-720 sequesters lymphocytes in the secondary lymphoid organs by inducing receptor internalization and degradation, thus sparing the central nervous system (CNS) from immune attack by autoreactive lymphocytes [13] [14] [15] . FTY-720 effectively decreases relapse rate up to 50% and is superior to interferon-β (IFN-β) therapy [16] [17] [18] . However, a subset of relapsing remitting MS (RRMS) patients on FTY-720 therapy develop severe relapses and even tumorfactive MS lesions despite severe lymphopenia [19] [20] [21] . This finding suggests that S1P signaling may participate in immune regulatory functions other than lymphocyte trafficking. S1P 1 receptor internalization is a crucial step in initiating S1P signaling 22, 23 . This process is dependent on post-translational modification of the C-terminal domain of the receptor [24] [25] [26] . Binding of S1P to S1P 1 promotes the phosphorylation of C-terminal domain serine residues of S1P 1 by protein kinase GRK2 (ref. 24 ). This covalent addition of phosphate residues modifies the physicochemical properties of S1P 1 , leading to internalization of the ligand-receptor complex. Impaired internalization of S1P 1 has been associated with arrested lymphocyte egress into the circulation and delayed lymphopenia in response to FTY-720 treatment 25, 27 . However, the physiological function of receptor internalization, subsequent effects on intracellular signaling pathways and how these effects modulate autoimmune neuroinflammation are yet to be determined.
Here, an unbiased, phosphoproteomic analysis of MS patient brain samples during active inflammation revealed that S1P 1 was phosphorylated in vivo on S351. S1P 1 expression was also observed in brain-infiltrating T lymphocytes in MS lesions, as shown by immunohistochemistry. Complementary to our findings in the human disease, induction of EAE in mice carrying the phosphorylation-defective S1P 1 receptor (S1P 1 (S5A) mice) resulted in severe paralysis, more interleukin 17 (IL-17)-mediated inflammation in the peripheral immune system and higher numbers of IL-17-expressing CD4 + T cells infiltrating the CNS. We also showed that the severe autoimmune neuroinflammation in the S1P 1 (S5A) mice was due to activation of the Jak-STAT3-IL-17 signaling pathway and that signaling via S1P 1 was directly responsible for this effect. Finally, we showed that STAT3-mediated T H 17 polarization in S1P 1 (S5A) mice was dependent on IL-6 signaling. Collectively, these data suggest that S1P 1 signaling is crucial for T H 17 polarization and the clinical outcome in MS.
RESULTS

S1P 1 was phosphorylated in MS brain lesions
We performed phosphoproteomic analysis of fresh-frozen brain tissue from autopsy samples of MS patients to identify dysregulated pathways during MS pathogenesis. We first characterized the histopathological and cellular features of MS brain lesion samples by conventional staining methods (hematoxylin and eosin, Luxol Fast Blue and Bielschowsky) and immunohistochemistry. The MS lesions included in our study were classically characterized as chronic active lesions, the most common lesion type observed in RRMS patients. There was evidence of active inflammation (infiltration of T cells and macrophages in the peri-venular region and the brain parenchyma), myelin loss, axonal damage, astrocytosis and microglia activation ( Supplementary Fig. 1a-d) 28, 29 .
Tissue containing six individual MS brain lesions (from three MS patients) was then pooled and subjected to phosphoproteomic analysis by mass spectrometry 30 . MS lesions and control brain samples were homogenized separately, and the respective protein extracts were digested with protease trypsin. Peptide pools were then fractionated, phosphopeptides were enriched, and fractions containing phosphopeptide mixtures were analyzed by nano-flow liquid chromatography and mass spectrometry ( Supplementary Fig. 2 ). Identified phosphopeptides were selected according to stringent criteria, based on X corr (the observed-to-theoretical mass spectrum crosscorrelation), ∆Cn (the difference of normalized cross-correlation scored between the first and second peptide search hits) and a falsepositive rate (FDR) less than 0.6%, to ensure the reliability of sequence identification and assignment of modifications 31 .
This analysis identified a total of 7,404 unique phosphorylation sites, 6,035 from MS samples and 3,802 from controls (Supplementary Table 1 , page 1). MS samples contained more phosphorylated proteins and more phosphorylation sites within individual proteins. Serine phosphorylation sites were most abundant (4,766 from MS samples, 2,998 from control samples, and a total of 5,785 unique sites), followed by threonine sites (1,101 MS, 696 control and 1,401 total) and tyrosine sites (168 MS, 108 control and 218 total) (Supplementary Table 1 ). The analysis identified a total of 2,633 phosphoproteins; 2,243 were found in MS samples and 1,639 in control brains (Supplementary Table 1 ). Many of these proteins were phosphorylated on multiple sites.
We further explored the functional roles of these phosphoproteins to identify dysregulated pathways. Phosphoproteins from MS and control samples were selected on the basis of the spectral count of phosphorylation sites (that is, the ratio of phosphorylation sites from phosphopeptides identified from MS samples to those identified from control samples). These data were then uploaded into the Database for Annotation, Visualization and Integrated Discovery (DAVID) bioinformatic analysis system and clustered 32, 33 . We observed differential functional enrichment patterns in MS and control samples, as indicated by the Benjamini P values (Supplementary Fig. 3 ). Among these differences were several pathways involved in regulating immune response (such as T cell receptor signaling or chemokine signaling) and trafficking (including VEGF signaling, leukocyte transmigration, adherens or tight junction formation), which were substantially upregulated in samples from active MS lesions.
Among the identified phosphopeptides from MS samples were four unique phosphopeptides belonging to S1P 1 (S1P 1 (342-352)), a GPCR that is a key regulator of immune cell egress (Fig. 1a) . The fragmentation pattern and b and y ions from the mass spectra of S1P 1 (342-352)
Anti-S1P 1 Anti-GFAP Anti-S1P 1 Anti-CD3 A r t i c l e s peptide unequivocally indicated the addition of a phosphate group on S351, on the carboxyl-terminal tail of S1P 1 . The carboxyl terminus of S1P 1 has previously been identified as a crucial region for S1P signaling, mediating phosphorylation-dependent receptor internalization 24 . This phosphopeptide was identified in the phosphopeptide fractions from the active MS brain lesions, suggesting that phosphorylation of S351 may be important in MS pathogenesis.
We then investigated which cells expressed S1P 1 in active MS brain lesions. We performed immunohistochemistry on formalin-fixed, paraffin-embedded sections of the same brain samples we used in our phosphoproteomic analysis. We used antibodies against S1P 1 , T cells (anti-CD3) and glia (astrocytes, anti-glial fibrillary acidic protein (GFAP)) on serial sections from several MS brain samples containing active lesions to visualize expression of S1P 1 on different cell types in the CNS. S1P 1 was strongly expressed in the infiltrating CD3 + T cells in the active MS brain lesions (Fig. 1b,c and Supplementary  Fig. 4 ). S1P 1 expression was also observed in GFAP-positive glial cells ( Fig. 1d,e and Supplementary Fig. 5 ). However, we could not investigate the state of S1P 1 phosphorylation in these cells using this method owing to the lack of a phospho-specific S1P 1 antibody. These findings suggest that S1P 1 was expressed in T cells and astrocytes in MS during active CNS inflammation. S1P 1 (S5A) mice developed more severe EAE Phosphorylation events serve as molecular switches to propagate cellular signaling events under physiological and pathological conditions 30, 34, 35 . Phosphorylation on the C-terminal serines of S1P 1 has been shown to initiate receptor internalization and regulate lymphocyte egress from lymphoid organs into the circulation 25, 27 . Mice harboring a mutated S1pr1 gene encoding S1P 1 (S5A), a phosphorylation-defective S1P 1 receptor with five serines changed to alanines in the C-terminal peptide, have normal immune cell counts and receptor function under physiological conditions, but show delayed lymphopenia in response to treatment with FTY-720 (ref. 25) . Our findings of S1P 1 phosphorylation in active MS brain lesions and S1P 1 expression in T cells led us to investigate the effects of S1P 1 phosphorylation on autoimmune neuroinflammation using the S1P 1 (S5A) mice. We induced EAE in S1P 1 (S5A) and wild-type C57BL/6J mice with complete Freund's adjuvant and MOG (myelin oligodendrocyte glycoprotein) peptide. S1P 1 (S5A) mice developed earlier onset of EAE and more severe paralysis compared with their wild-type counterparts ( Fig. 2a and Supplementary Table 2 ).
We also observed more proliferation of splenocytes from S1P 1 (S5A) EAE mice (day 8 after immunization) in response to ex vivo reactivation with MOG 35-55 peptide (Fig. 2b) . In addition, analysis of culture supernatants by enzyme-linked immunosorbent assay (ELISA) revealed that splenocytes from S1P 1 (S5A) mice expressed higher concentrations of the inflammatory cytokines IL-2, IL-6, TNF and IL-17 ( Fig. 2c) . Similar results were also seen in lymph node cell cultures of S1P 1 (S5A) EAE mice ( Supplementary Fig. 6a,b) . Histopathological analysis revealed that the CNS of S1P 1 (S5A) EAE mice contained more numerous inflammatory foci than the CNS of their wild-type counterparts (Fig. 2d,e) . These data suggest that defective phosphorylation of S1P 1 resulted in more severe autoimmune inflammation in the peripheral immune system and the CNS of S1P 1 (S5A) EAE mice.
Enhanced T H 17-mediated neuroinflammation in S1P 1 (S5A) mice S1P 1 is ubiquitously expressed and participates in diverse cellular processes, including maintaining vascular and immune functions in health and disease [36] [37] [38] [39] . To determine whether the increased EAE disease severity in the S1P 1 (S5A) mice was intrinsic to lymphocytes, we performed an adoptive transfer experiment in which we transferred encephalitogenic cells (MOG 35-55 -reactivated, expanded T cells) from wild-type C57BL/6J or S1P 1 (S5A) EAE mice into naive Rag1 −/− recipients. We found that the recipients of cells from S1P 1 (S5A) EAE mice developed more severe paralysis, similar to the more severe disease course observed in the S1P 1 (S5A) EAE mice ( Fig. 3a and Supplementary Table 3 ). These findings suggest that the primary determinant of the EAE phenotype in S1P 1 (S5A) mice was T cellintrinsic impaired S1P 1 signaling.
We then investigated the cellular mechanism of immune activation in S1P 1 (S5A) mice by profiling the immune cells in the peripheral immune system and CNS during the EAE disease course. Splenocyte counts tended to be higher in S1P 1 (S5A) EAE mice compared with their wild-type counterparts (Supplementary Fig. 7a ). However, the CNS of MOG 35-55 -immunized S1P 1 (S5A) EAE mice contained significantly more infiltrating immune cells compared with the CNS of wild-type EAE mice (Fig. 3b) throughout the EAE disease course (presymptomatic (day 8), peak of disease (day 13) and plateau stage (day 16); Supplementary Fig. 7b ). Characterization by flow cytometric analysis using CD45 staining suggested that these were indeed immune cells (Supplementary Fig. 7c ). There were also higher number of myeloid lineage (CD45 + CD11b + ) cells, suggesting enhanced immune cell trafficking and CNS inflammation in the S1P 1 (S5A) EAE mice (Supplementary Fig. 7d ).
Further characterization of CNS-infiltrating immune cells showed that there were significantly higher numbers of CD4 + T cells in the CNS of S1P 1 (S5A) mice (Fig. 3c) . Many of these cells expressed IL-17, as shown by flow cytometry after intracellular cytokine staining, in contrast with their wild-type counterparts (Fig. 3d,e ). However, there was no substantial difference in IFN-γ production in the CD4 + T cells from the CNS of S1P 1 (S5A) and wild-type EAE mice, suggesting selective activation of pathways involved in T H 17 differentiation (data not shown). Transcription factor NF-κB, p38 MAPK kinase and Jak-STAT pathways contribute to proinflammatory responses in autoimmune neuroinflammation 40, 41 . To investigate which of these pathways were activated in S1P 1 (S5A) EAE mice, we performed immunoblot analysis of splenocytes from MOG 35-55 -immunized, presymptomatic (day 8 after immunization) wild-type and S1P 1 (S5A) EAE mice. There was significantly more STAT3 phosphorylation in the splenocytes of S1P 1 (S5A) EAE mice (Fig. 3f,g and Supplementary Fig. 8a,b) .
We then investigated whether the surface residency of S1P 1 had effects on other proinflammatory pathways involved in autoimmune neuroinflammation, such as the NF-κB and the p38 MAPK pathways. Immunoblot analysis of splenocytes from wild-type and S1P 1 (S5A) EAE mice revealed that expression of p38, phosho-p38 and IκBα was not significantly altered in S1P 1 (S5A) EAE mice compared with their wild-type counterparts ( Fig. 3h and Supplementary  Fig. 8c-e ). These findings strongly suggest that enhanced inflammatory response in S1P 1 (S5A) mice was due to activation of the IL-17-STAT3 signaling pathway.
S1P-S1P 1 signaling directly activated T H 17 polarization
We next examined whether signaling via S1P 1 was directly responsible for enhanced T H 17 polarization in S1P 1 (S5A) EAE mice. We used several different approaches, including in vitro activation with the physiological ligand S1P; in vivo treatment of EAE mice with the sphingosine lyase inhibitor 2-acetyl-5-tetrahydroxybutyl imidazole (THI); suppression of IL-17 expression with the S1P 1 -specific inhibitor W146; S1pr1-specific siRNA knockdown; and in vitro activation using S1P 1 -deficient T cells 26, [42] [43] [44] .
First, we cultured splenocytes from MOG 35-55 -immunized wildtype and S1P 1 (S5A) EAE mice (day 8 after immunization) in the presence or absence of the physiological ligand S1P and quantified STAT3 phosphorylation by immunoblot analysis. We observed substantial STAT3 phosphorylation in both S1P 1 (S5A) and wild-type EAE splenocytes (Fig. 4a,b) , an effect decreased by incubation in the presence of the S1P 1 inhibitor W146.
Next, we investigated whether enhanced S1P signaling promoted IL-17 production in vivo. S1P is metabolized into phosphatidylethanolamine and hexadecenal by S1P lyase (SL) under physiological conditions 45 . The SL inhibitor THI blocks this process, resulting in increased tissue concentrations of S1P and enhanced S1P 1 signaling 43 . We treated MOG -immunized wild-type EAE mice with THI or vehicle control in vivo, isolated splenocytes on day 8, cultured them in the presence of MOG peptide and analyzed the culture supernatants by ELISA. Splenocytes from THI-treated mice expressed high concentrations of inflammatory cytokines, especially IL-17, suggesting that exposure to high concentrations of S1P in vivo enhanced IL-17 expression ( Fig. 4c) .
As W146 treatment decreased STAT3 phosphorylation, we next determined whether W146 antagonism of S1P 1 function could abrogate enhanced IL-17 expression in S1P 1 (S5A) mice. Activation of naive S1P 1 (S5A) splenocytes in vitro with anti-CD3 and anti-CD28 in the presence of W146 significantly decreased IL-17 expression in a dose-dependent manner (Fig. 4d) . Similar results were also obtained with wild-type CD3 + cells (data not shown).
Finally, we used genetic tools to investigate the connection between S1P 1 signaling and T H 17 polarization. CD3 + T cells from naive S1P 1 (S5A) mice were activated in vitro with anti-CD3 and anti-CD28 in the presence of S1pr1-specific siRNA. There was significantly less IL-17 expression in the culture supernatants when cells were incubated in the presence of S1pr1-specific siRNA ( Fig. 4e-g) . These findings were confirmed by experiments using S1P 1 -deficient T cells. CD3 + T cells from S1P 1 conditional knockout mice (S1pr1 f/f Rosa26-CreER T2 ; S1pr1 f/f crossed with Rosa26-CreER T2 after tamoxifen treatment), activated in vitro with anti-CD3 and anti-CD28, expressed less IL-17 compared with CD3 + cells from their wild-type counterparts (Fig. 4h) . Collectively, these data support the premise that S1P 1 signaling directly modulates IL-17 expression. S1P 1 -mediated T H 17 polarization was IL-6-dependent We next investigated whether T cells or antigen-presenting cells (APCs) were crucial for S1P 1 -mediated T H 17 polarization. We performed a mixed-lymphocyte culture experiment in which we cocultured CD3 + cells from MOG -immunized (day 8, presymptomatic) wild-type and S1P 1 (S5A) mice with naive irradiated-wild type A r t i c l e s or S1P 1 (S5A) APCs in the presence of MOG antigen. We then quantified IL-17 expression in the culture supernatant by ELISA. Cultures containing T cells, APCs or both from S1P 1 (S5A) mice expressed significantly more IL-17 than those containing wild-type T cells and APCs (Fig. 5a) . These findings suggest that S1P 1 (S5A) T cells were crucial, but S1P 1 (S5A) APCs also acted synergistically to enhance IL-17 expression.
We then investigated which cytokines expressed by APCs might promote Th17 differentiation. We measured the elicited IL-1β, IL-6, IL-10 and TNF concentrations in splenocyte cultures of S1P 1 (S5A) and wild-type EAE mice. IL-6 concentrations were significantly higher in the cultures from S1P 1 (S5A) mice compared with wild-type mice (Fig. 5b) . Expression of the other cytokines was not substantially different between the mutant and wild-type cells (data not shown).
IL-6 is a crucial factor in T H 17 polarization. To determine the role of IL-6 signaling in S1P 1 (S5A) EAE mice, we treated splenocytes from MOG 35-55 -immunized wild-type and S1P 1 (S5A) presymptomatic EAE mice in vitro with recombinant IL-6 or IL-6 neutralizing antibody and performed immunoblot analysis. IL-6 treatment enhanced STAT3 phosphorylation, especially in the S1P 1 (S5A) splenocytes, which was reversed by the addition of anti-IL-6 ( Fig. 5c,d) . Finally, we observed that IL-17 expression from the splenocytes of S1P 1 (S5A) presymptomatic EAE mice was abolished by direct inhibition of either STAT3 (with the STAT3 inhibitor Stattic) or the upstream regulator (c) Cytokine expression in splenocyte cultures of MOG 35-55 -immunized WT EAE mice treated in vivo with the S1P lyase inhibitor THI (6.25 mg/kg, daily intraperitoneal injections). (d,e,h) IL-17 expression in CD3 + cells (activated with anti-CD3 and anti-CD28) from S1P 1 (S5A) naive mice treated in vitro with W146 (0-10 nM) (d); WT naive mice treated in vitro with scrambled control (Ctrl) or S1pr1-specific (S1pr1) siRNA (e); or naive S1pr1 +/+ (WT) or S1pr1 −/− (S1pr1 f/f Rosa26-CreER T2 ) mice (h). (f,g) Flow cytometric analysis of S1P 1 expression after treatment with S1pr1 or Ctrl siRNA. MFI, mean fluorescence intensity. *P < 0.05, **P < 0.01, Student's t-test. Data in c-e,h were analyzed by ELISA. Experiments in a,b,d-g were performed 3-5 times, and experiments in c,h twice. n = 3-5 mice per group. Bar graphs show means and s.e.m. npg of STAT3, Jak (with Jak inhibitor) ( Fig. 5e,f) . Similar results were also obtained from wild-type splenocytes (data not shown). These data suggest that S1P 1 -mediated T H 17 polarization was dependent on the IL-6-Jak-STAT3 pathway.
DISCUSSION
Here we have characterized the MS brain lesion phosphoproteome from histologically defined brain tissue samples from MS patients. To our knowledge, this is the first time such approach has been used to reveal dysregulated pathways in diseased tissue during MS pathogenesis. This unbiased approach has shed mechanistic insights on how S1P signaling modulates T H 17 differentiation, a key determinant of disease severity in MS. This exemplifies how system-wide analysis of pathological samples could lead to the discovery of mechanistic underpinnings that could potentially guide patient care.
The question of whether S1P 1 phosphorylation is detrimental or beneficial in the context of autoimmune demyelinating disease remains to be addressed. We observed enhanced S1P 1 phosphorylation in the human MS brain lesions, suggesting that S1P 1 phosphorylation correlates with worse CNS inflammation. However, worse EAE clinical phenotype and severe inflammation in the peripheral immune system and CNS in S1P 1 (S5A) EAE mice implied that receptor phosphorylation is crucial for downregulating autoimmune neuroinflammation. One possible explanation is that phosphorylation of S1P 1 is an attempt to downregulate T H 17 differentiation as a compensatory mechanism to shut down neuroinflammation. Reciprocal activation of S1P and STAT3 pathways resulting in aggressive tumor progression has been reported previously, but how this applies in the context of MS needs to be investigated further 46 . The downstream effects of S1P 1 phosphorylation may also be cell type specific. We observed S1P 1 expression in the brain-infiltrating T cells and astrocytes in active MS lesions. The current study mainly focused on the role of S1P signaling in the immune cells; future studies should investigate the effects of S1P signaling in the CNS cells, including astrocytes, where S1P 1 was also abundantly expressed.
Our findings suggest that the S1P 1 -STAT3 connection is at least in part dependent on IL-6 signaling. We have not yet explored how S1P signaling is linked to IL-6 expression. In our preliminary data, S1P 1 signaling does not seem to have major effects on the transcriptional regulation of IL-6 expression in T cells. Whether STAT3 is activated via GPCR signaling, and how the S1P pathway crosstalks with the IL-6-Jak-STAT3 pathway, remain to be investigated.
In summary, phosphoproteomic analysis of MS brain lesions revealed the S1P 1 -mediated STAT3 activation and showed that impaired S1P 1 receptor internalization may worsen autoimmune CNS inflammation. These findings raise several clinically relevant questions, such as whether FTY-720 therapy modulates T H 17 polarization and whether there is synergy with arresting lymphocyte trafficking. As an amino acid change (serine to alanine) in S1P 1 leads to worse CNS inflammation in EAE, further studies should also investigate whether MS patients carrying variations in the S1PR1 gene develop aggressive forms of MS, and their response to S1P receptor modulators should be evaluated. This may allow prognostication of MS disease course and response to immune modulatory therapies.
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